Flow Cytometry in Acute Leukemias: A Practical Guide for the Internist

Dr Neeraj Manikath , claude.ai

Abstract

Flow cytometry has revolutionized the diagnosis, classification, and monitoring of acute leukemias. This comprehensive review provides internists and hematology fellows with a practical framework for interpreting flow cytometry reports, understanding lineage determination, and recognizing clinically significant immunophenotypic patterns. We discuss the fundamental principles, marker panels, diagnostic algorithms, and prognostic implications while highlighting common pitfalls and expert pearls for clinical practice.

Introduction

Acute leukemias represent a heterogeneous group of clonal hematopoietic malignancies characterized by the accumulation of immature blast cells in the bone marrow and peripheral blood. The World Health Organization (WHO) classification system mandates ≥20% blasts for diagnosis, with flow cytometry serving as an indispensable tool for lineage assignment, prognostic stratification, and minimal residual disease (MRD) detection.1 Unlike morphology alone, which can be subjective and limited, flow cytometry provides objective, quantitative assessment of cellular antigens with high sensitivity and specificity.

Fundamental Principles

Flow cytometry analyzes individual cells suspended in fluid as they pass through laser beams. Fluorochrome-conjugated antibodies bind to specific cellular antigens, generating light signals detected by photomultiplier tubes. Modern instruments employ 8-10 colors simultaneously, allowing comprehensive immunophenotypic profiling from limited sample volumes.2

Pearl #1: The power of flow cytometry lies not in identifying single positive markers, but in recognizing aberrant antigen expression patterns—combinations that don't occur in normal hematopoiesis.

Essential Marker Panels

Screening Panel

Initial assessment typically includes:

Pan-leukocyte markers: CD45 (leukocyte common antigen)
Myeloid markers: CD13, CD33, CD117, MPO (myeloperoxidase)
B-lymphoid markers: CD19, CD10, CD20, cytoplasmic CD79a
T-lymphoid markers: CD2, CD3 (surface and cytoplasmic), CD5, CD7
Immaturity markers: CD34, HLA-DR, TdT (terminal deoxynucleotidyl transferase)

Acute Myeloid Leukemia (AML) Extended Panel

Additional markers help refine AML subtypes:

Monocytic differentiation: CD14, CD64, CD11b, CD36
Megakaryocytic: CD41, CD61
Erythroid: CD71, CD235a (glycophorin A)
Prognostic markers: CD56, CD7 (aberrant expression)

Pearl #2: CD117 is your friend in AML—it's expressed in 60-90% of cases and helps distinguish blasts from normal hematopoietic precursors.3

Acute Lymphoblastic Leukemia (ALL) Markers

B-ALL Maturation Stages

Flow cytometry reveals B-cell ontogeny:

Pro-B ALL: CD19+, CD10-, cytoplasmic CD79a+, TdT+
Common ALL: CD19+, CD10+, TdT+ (most common, 60-70%)
Pre-B ALL: CD19+, CD10+, cytoplasmic μ heavy chain+
Mature B-ALL: Surface immunoglobulin+, CD10+/-, TdT-

Oyster #1: CD10 positivity in B-ALL generally indicates better prognosis in children but this correlation is weaker in adults. However, CD10-negative pro-B ALL often harbors KMT2A (MLL) rearrangements with poorer outcomes.4

T-ALL Characteristics

T-ALL comprises 15-25% of adult ALL and 10-15% of pediatric ALL:

Immature T-ALL: CD7+, cytoplasmic CD3+, surface CD3-
Cortical T-ALL: CD1a+, CD4+CD8+ (double positive)
Mature T-ALL: Surface CD3+, either CD4+ or CD8+

Hack #1: If you see bright CD45 expression with absent CD19 and aberrant CD13/CD33 co-expression, think T-ALL. The aberrant myeloid markers don't change the diagnosis—it's still T-ALL, not mixed phenotype acute leukemia (MPAL).

Mixed Phenotype Acute Leukemia (MPAL)

MPAL represents <5% of acute leukemias and requires stringent criteria defined by the WHO classification:5

Myeloid lineage assignment requires:

MPO (by flow or cytochemistry) OR
Monocytic differentiation (≥2 of: NSE, CD11c, CD14, CD64, lysozyme)

T-lineage assignment requires:

Surface or cytoplasmic CD3

B-lineage assignment requires:

Strong CD19 with at least one of: CD79a, CD10, or CD22

Oyster #2: Don't overcall MPAL. Aberrant expression of 1-2 markers from another lineage is common in both AML and ALL. True MPAL requires meeting full lineage-defining criteria for multiple lineages, not just "sprinklings" of cross-lineage antigens.

Diagnostic Approach: A Systematic Framework

Step 1: Identify the Blast Population

Use CD45 vs. side scatter (SSC) gating. Blasts typically show:

Dim to moderate CD45 expression
Low to intermediate side scatter
CD34 and/or HLA-DR positivity (except in APL and rare variants)

Hack #2: The CD45/SSC plot is your roadmap. Normal lymphocytes cluster in high CD45/low SSC; monocytes in high CD45/intermediate SSC; granulocytes in intermediate CD45/high SSC. Blasts usually sit in the dim CD45/low-intermediate SSC region.

Step 2: Determine Lineage

For AML:

MPO positivity is definitive (≥3% by cytochemistry or any by flow)
CD13, CD33, CD117 support myeloid lineage
Absence of lymphoid markers (CD19, CD3)

For B-ALL:

CD19 positivity is mandatory
Typically: CD19+, CD10+/-, TdT+, CD20-/dim, CD34+/-
Surface light chain restriction confirms mature B-ALL

For T-ALL:

Cytoplasmic CD3 (most sensitive)
CD7 usually positive
Variable CD2, CD5, surface CD3

Step 3: Identify Aberrancies

Look for:

Asynchronous expression (immature + mature markers)
Cross-lineage expression (myeloid markers on lymphoblasts)
Overexpression or underexpression compared to normal
Missing expected antigens

Pearl #3: Create a mental "leukemia-associated immunophenotype" (LAIP) at diagnosis. This fingerprint becomes invaluable for MRD monitoring. Even detecting 0.01% cells with the original LAIP can indicate residual disease.6

Special Entities and Their Flow Signatures

Acute Promyelocytic Leukemia (APL)

This medical emergency has a distinctive immunophenotype:

CD34 negative (critical!)
HLA-DR negative or dim
Bright CD33, heterogeneous CD13
Variable CD2 expression
MPO intensely positive

Oyster #3: The absence of CD34 and HLA-DR in an acute leukemia should immediately raise suspicion for APL. Initiate ATRA (all-trans retinoic acid) pending genetic confirmation of PML-RARA, as delays increase early mortality from disseminated intravascular coagulation (DIC).7

AML with Monocytic Differentiation

Acute myelomonocytic leukemia (AMMoL, M4) and acute monoblastic leukemia (AMoL, M5):

CD14+, CD64+, CD11b+, CD36+
Often HLA-DR positive (unlike APL)
CD34 variable
May show high CD4 expression

Hack #3: High CD56 expression in monocytic AML often correlates with extramedullary disease, particularly CNS involvement, and warrants prophylactic intrathecal chemotherapy.8

AML with Megakaryoblastic Differentiation

Seen in Down syndrome and infants:

CD41 (GPIIb/IIIa) and/or CD61 (GPIIIa) positive
Often CD34+, CD117+
May be CD45 negative/dim

Prognostic Applications

Flow cytometry provides prognostic information beyond lineage assignment:

Favorable indicators:

Core binding factor leukemias show specific patterns
NPM1-mutated AML: typically CD34-negative, HLA-DR+, CD123+

Unfavorable indicators:

CD56 expression in AML (especially with t(8;21))
CD7 expression in AML
Complex/aberrant phenotypes
High CD34 percentage in certain contexts

Pearl #4: In B-ALL, very early precursor phenotype (lack of CD10, expression of myeloid or T-cell markers) identifies a high-risk subset requiring intensified therapy.9

Minimal Residual Disease Monitoring

MRD assessment by flow cytometry has become standard of care:

Key principles:

Sensitivity: 0.01% (1 in 10,000 cells) with multicolor flow
Requires 2-3 million cells for optimal sensitivity
Time points: Post-induction, post-consolidation, pre-transplant
Predictive value: MRD positivity strongly predicts relapse

Hack #4: When reviewing MRD reports, focus on two numbers: (1) the percentage of abnormal cells, and (2) the number of events acquired. A report of "0.05% positive" based on 50,000 events is less reliable than one based on 2 million events.

Oyster #4: Flow-MRD and molecular MRD (PCR-based) are complementary, not interchangeable. Flow detects the immunophenotype, PCR detects genetic markers. In some leukemias (like NPM1-mutated AML), PCR is more sensitive; in others, flow is superior.10

Common Pitfalls and How to Avoid Them

1. Hematogones vs. B-ALL Blasts

Hematogones (normal B-cell precursors) regenerate after chemotherapy and can mimic B-ALL:

Hematogones: Show continuous maturation spectrum, dim CD20 gradually increasing, CD34 brightness decreasing through maturation stages
B-ALL: More homogeneous population, often aberrant CD20 or CD34 expression patterns

Hack #5: Look for the "maturation continuum." Hematogones show smooth progression from immature (CD34+CD10++) to mature (CD34-CD10+CD20+). Leukemic blasts cluster tightly without this spectrum.

2. Viable vs. Non-viable Cells

Poor sample quality leads to false interpretations:

Always check viability markers (7-AAD, DAPI)
Degenerating cells lose surface antigens
Time from collection matters—analyze within 24-48 hours

3. Overinterpretation of Single Markers

Pearl #5: Never diagnose leukemia on one antigen. Require confirmatory marker combinations. CD34+ cells exist normally; CD34+/MPO+/CD13+/CD33+ with aberrant patterns defines AML.

4. Ignoring Clinical Context

Flow cytometry must be interpreted with:

Morphology (gold standard remains integration)
Cytogenetics and molecular testing
Clinical presentation
Prior therapy history

Integration with Molecular Diagnostics

Modern leukemia diagnosis requires integrated approaches:

Complementary roles:

Flow: Rapid lineage assignment, immunophenotyping
Cytogenetics: Detect translocations, chromosomal gains/losses
Molecular: Identify mutations (FLT3, NPM1, CEBPA, etc.)
FISH: Targeted genetic abnormality detection

Certain immunophenotypes predict genetic abnormalities:

CD19+CD10+CD34+ in B-ALL → Consider BCR-ABL1 testing
CD34-HLA-DR- in AML → APL with PML-RARA (>95% sensitivity)
High CD123 expression → Possible plasmacytoid dendritic cell neoplasm

Future Directions

Emerging technologies enhance flow cytometry's utility:

Spectral flow cytometry: Enables 30+ parameter analysis, improving rare event detection and complexity handling.

Automated analysis: Machine learning algorithms reduce inter-observer variability and enhance pattern recognition.

Single-cell multi-omics: Combining immunophenotype with transcriptomics provides unprecedented resolution of leukemic heterogeneity.

Practical Summary: The "Rule of 3s"

For quick clinical application, remember:

Three questions for every flow report:

What percentage are blasts (≥20% for leukemia)?
What lineage (myeloid, B-lymphoid, T-lymphoid, or mixed)?
What aberrancies define the LAIP for MRD tracking?

Three red flags demanding immediate action:

CD34-/HLA-DR- myeloid blasts → Suspect APL, start ATRA
High WBC with T-ALL features → Risk of tumor lysis, respiratory distress
High-risk features (complex immunophenotype, adverse markers) → Escalate therapy discussions

Three things flow cytometry cannot do:

Replace morphologic examination
Detect all genetic abnormalities
Determine primary vs. secondary leukemia (requires clinical history)

Conclusion

Flow cytometry has transformed acute leukemia diagnosis from a purely morphologic exercise to a precise, quantitative science. For internists and hematologists, understanding basic flow cytometry interpretation enables accurate diagnosis, appropriate risk stratification, and optimal therapeutic decision-making. The key lies not in memorizing every antigen, but in recognizing patterns, appreciating aberrancies, and integrating flow data with clinical context and complementary diagnostics.

As precision medicine advances, flow cytometry's role continues expanding beyond diagnosis to encompass MRD monitoring, treatment response prediction, and therapeutic target identification. Mastery of flow cytometry interpretation represents an essential skill for modern hematology practice, bridging laboratory sophistication with bedside clinical care.

References

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941-3967.
Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980-2988.
Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014073.
Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113(9):1906-1908.
Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-1291.
Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126-5135.
Suzuki R, Murata M, Zheng J, et al. Expression of adhesion molecules and CD56 in acute myeloid leukemia: association with extramedullary involvement. Leuk Lymphoma. 2005;46(7):1007-1012.
Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4(10):1413-1420.
Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31(7):1482-1490.

Conflict of Interest: None declared.

Word Count: 2,000 words (excluding references)

Search This Blog

Internal medicine